NCT02857270 2022-11-22
A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer
Eli Lilly and Company
Phase 1 Completed
Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company